Noni contains competitive ligand(s) binding to GABAa agonist receptors as an anxiolytic

AGFD 67

Shixin Deng, shixin_deng@tni.com, Afa K Palu, afa_palu@tni.com, Bing-Nan Zhou, bing_nan_zhou@tni.com, Jarakae C. Jensen, and Brett J West, brett_west@tni.com. Research and Development Department, Tahitian Noni International, 737 East, 1180 South, American Fork, UT 84003
Morinda citrifolia is a small tropical evergreen shrub or tree indigenous to Pacific Islands, Southeast Asia, and some other areas, and commonly called Noni. The fruit of Noni has been used for the treatment of many diseases including cold, flu, diabetics, hypertension and cancer in fork medicines for thousands of years. Among its broad medicinal applications, Noni was reported to have sedative and anxiolytic effects in vivo. In our study, in vitro biological mechanism of Noni as an anxiolytic is explored. The experimental result indicated that methanol crude extract of Noni exhibited 75% inhibition on the binding of [3H] muscimol to the gamma-aminobutyric acid A (GABAa) inhibitory neurotransmitter receptors at a concentration of 100 g/mL. Further phytochemical study revealed that active ligands are located at hydrophilic portion of Noni, butanol and water fractions showed 78% and 81% inhibitory effects to the radioligand binding to GABAa receptors (100 g/mL), respectively. This study demonstrated that Noni contains GABAnergic ligand(s) which can competitively bind to GABAa receptors as an agonist to elicit the sedative and anxiolytic effects of Noni.
 

General Posters
1:00 PM-3:00 PM, Monday, 11 September 2006 Moscone Center -- Hall D, Poster

Sci-Mix
8:00 PM-10:00 PM, Monday, 11 September 2006 Moscone Center -- Hall D, Sci-Mix

Division of Agricultural & Food Chemistry

The 232nd ACS National Meeting, San Francisco, CA, September 10-14, 2006